Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 01.05.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | to Section 13(a) of the Exchange Act. o Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Ap |
Stammdaten
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Unternehmen & Branche
| Name | Vaxcyte, Inc. |
|---|---|
| Ticker | PCVX |
| CIK | 0001649094 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 8,41 Mrd. USD |
| Beta | 1,39 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -766,628,000 | -5.63 | 3,002,717,000 | 2,685,510,000 | |
| 2025-09-30 | 10-Q | -212,830,000 | -1.56 | 3,171,600,000 | 2,892,882,000 | |
| 2025-06-30 | 10-Q | -166,573,000 | -1.22 | 3,305,363,000 | 3,071,334,000 | |
| 2025-03-31 | 10-Q | -140,718,000 | -1.04 | 3,378,103,000 | 3,200,026,000 | |
| 2024-12-31 | 10-K | -463,927,000 | -3.80 | 3,511,318,000 | 3,305,819,000 | |
| 2024-09-30 | 10-Q | -103,124,000 | -0.83 | 3,559,746,000 | 3,417,634,000 | |
| 2024-06-30 | 10-Q | -128,703,000 | -1.10 | 2,087,267,000 | 1,986,132,000 | |
| 2024-03-31 | 10-Q | -95,020,000 | -0.85 | 2,091,305,000 | 1,983,983,000 | |
| 2023-12-31 | 10-K | -402,266,000 | -4.14 | 1,407,917,000 | 1,240,468,000 | |
| 2023-09-30 | 10-Q | -92,664,000 | -0.91 | 1,496,057,000 | 1,402,716,000 | |
| 2023-06-30 | 10-Q | -68,339,000 | -0.70 | 1,502,819,000 | 1,433,376,000 | |
| 2023-03-31 | 10-Q | -60,462,000 | -0.70 | 1,008,163,000 | 944,771,000 | |
| 2022-12-31 | 10-K | -223,485,000 | -3.44 | 1,006,178,000 | 953,613,000 | |
| 2022-09-30 | 10-Q | -57,917,000 | -0.93 | 412,065,000 | 359,311,000 | |
| 2022-06-30 | 10-Q | -48,532,000 | -0.80 | 411,619,000 | 366,500,000 | |
| 2022-03-31 | 10-Q | -38,986,000 | -0.68 | 402,717,000 | 359,543,000 | |
| 2021-12-31 | 10-K | -100,077,000 | -1.93 | 324,337,000 | 284,018,000 | |
| 2021-09-30 | 10-Q | -26,615,000 | -0.51 | 354,068,000 | 305,956,000 | |
| 2021-06-30 | 10-Q | -23,679,000 | -0.46 | 358,054,000 | 317,025,000 | |
| 2021-03-31 | 10-Q | -21,220,000 | 382,351,000 | 326,937,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-01 | Wassil Jim | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -1,412 | 58.14 | -82,090.86 | -44,8% | |
| 2026-04-01 | Wassil Jim | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -838 | 58.93 | -49,385.02 | -27,0% | |
| 2026-03-17 | Cowan Elvia | Officer, SVP, Finance & CAO | Open Market Sale | -405 | 56.26 | -22,786.52 | -12,4% | |
| 2026-03-17 | Cowan Elvia | Officer, SVP, Finance & CAO | Open Market Sale | -1,487 | 55.39 | -82,360.47 | -45,0% | |
| 2026-03-11 | Cowan Elvia | Officer, SVP, Finance & CAO | Open Market Sale | -2,500 | 58.59 | -146,481.75 | -80,0% | |
| 2026-03-10 | Wassil Jim | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -4,968 | 59.16 | -293,906.88 | -160,6% | |
| 2026-03-10 | Wassil Jim | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -2,427 | 58.32 | -141,532.93 | -77,3% | |
| 2025-12-31 | Dhaliwal Harpreet S. | Officer, Chief Technical Ops Officer | Open Market Sale | -9,743 | 46.69 | -454,890.93 | -248,5% | |
| 2025-12-23 | Cowan Elvia | Officer, SVP, FINANCE | Open Market Sale | -4,907 | 47.90 | -235,040.39 | -128,4% | |
| 2025-12-23 | Cowan Elvia | Officer, SVP, FINANCE | Open Market Sale | -6,716 | 47.94 | -321,931.46 | -175,9% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.